Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOTEM-RRMS: Testosterone undecanoate in relapsing remitting multiple sclerosis with hypogonadism
2024-517845-14-00Phase 2Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Nebido (testosterone undecanoate) + standard MS DMT with Placebo to Nebido + standard MS DMT (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Oct 2024; status: authorised.
02
Drugs
testosterone undecanoate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-517845-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517845-14-00.